

Academic Accomplishments 2016 (Inova authors bolded)

ORIGINAL RESEARCH MANUSCRIPTS

1. Noble PW, Albera C, Bradford WZ, Costabel U, du Bois RM, Fagan EA, Fishman RS, Glaspole I, Glassberg MK, Lancaster L, Lederer DJ, Leff JA, **Nathan SD**, Pereira CA, Sahn SA, Swigris JJ, Valeyre D, King TE. Pirfenidone for idiopathic pulmonary fibrosis: Analysis of pooled data from three multinational Phase 3 trials. *Eur Respir J*. 2016 Jan;47(1):243-53.
2. Crawford EL, Levin A, Safi F, Liu M, Baugh A, Zhang X, Yeo J, Khuder SA, Boulos AM, Nana-Sinkam P, Massion P, Arenberg DA, Midthun D, Mazzone PJ, **Nathan SD**, Wainz R, Silvestri G, Tita J, Willey JC. Lung Cancer Risk Test Trial: Study Design, Participant Baseline Characteristics, Safety, and Establishment of Biospecimen Bank. *BMC Pulmonary Medicine* 2016 16:16 DOI 10.1186/s12890-016-0178-4
3. Lancaster L, Albera C, Bradford WZ, Costabel U, du Bois RM, Fagan EA, Fishman RS, Glaspole I, Glassberg MK, King TE, Lederer DJ, Lin Z, **Nathan SD**, Pereira CA, Swigris JJ, Valeyre D, Noble PW. Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis: Integrated Analysis of Cumulative Data from 5 Clinical Trials. *BMJ Open Res* 2016;3:e000105. doi:10.1136/bmjresp-2015-000105
4. **Shin S, King CS, Puri N, Shlobin OA, Brown AW, Ahmad S, Weir N, Nathan SD**. Pulmonary artery size as a predictor of outcomes in idiopathic pulmonary fibrosis. *Eur Respir J* 2016; 47: 1445–1451
5. **Nathan SD**, Albera C, Bradford WZ, Costabel U, du Bois RM, Fagan EA, Fishman FS, Glaspole I, Glassberg MK, Glasscock KF, King TE, Lancaster L, Lederer DJ, Lin Z, Pereira CA, Swigris JJ, Valeyre D, Noble PW, Wells A. Effect of Continued Treatment with Pirfenidone Following Clinically Meaningful Declines in Forced Vital Capacity: Analysis of Data from Three Phase 3 Trials in Patients with Idiopathic Pulmonary Fibrosis. *Thorax*. 2016 *Thorax* 2016;71:429-435
6. Albera C, Costabel U, Fagan EA, Glassberg MK, Gorina E, Tang H, Lancaster L, Lederer DJ, **Nathan SD**, Spirig D, Swigris JJ. Efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis with more preserved lung function. *Eur Res J* 2016;48:843-51
7. Fischer A, Gillies H, Blair C, Tislow JD, **Nathan SD**. Ambrisentan Response in Connective Tissue Disease-Associated Pulmonary Arterial Hypertension- Subgroup Analysis of the ARIES-E Clinical Trial. *Respiratory Medicine* 2016;117:254-263.
8. **Hong A, King CS, Brown AW, Ahmad S, Shlobin OA, Khandhar S, Bogar L, Burton N, Rongione A, Nathan SD**. Hemothorax Following Lung Transplantation: Incidence, Risk Factors, and Effect on Morbidity and Mortality. *Multidisciplinary Respiratory Medicine* 2016 11:40 DOI 10.1186/s40248-016-0075-y
9. **Nathan SD**, Albera C, Bradford WZ, Costabel U, Glaspole I, Glassberg MK, Kardatzk DR, Daigl M, Kirchgassler K, Lancaster LH, Lederer DJ, Pereira CA, Swigris JJ, Valeyre D, Noble PW. Effect of Pirfenidone on Mortality: Pooled and Meta Analyses of Three Phase 3 IPF Clinical Trials. accepted to *Lancet Res* 9/29/16
10. Kearon C, Akl E, Ornelas J, Blaivas A, Jimenez D, Bournaemeaux H, Huisman M, **King CS**, Morris T, Sood N, Stevens S, Vintch J, Wells P, Woller S, Moores L. Antithrombotic therapy for VTE Disease: Chest Guideline and Expert Panel Report. *Chest*. 2016; 149(2): 315-352.

REVIEWS

1. **Brown AW, Kaya H, Nathan SD**. Lung Transplantation in Interstitial Idiopathic Pneumonia: A Review. *Respirology* 2016 21:1173–1184
2. **Nathan SD**, Behr J, Cottin V, Collard HR, Hoepfer MM, Martinez FJ, Wells AU. Idiopathic interstitial pneumonia-associated pulmonary hypertension: A target for therapy? *Res Med* 5-NOV-2016 DOI information: 10.1016/j.rmed.2016.11.003
3. Anderson A, Shifren A, **Nathan SD**. A safety evaluation of pirfenidone for the treatment of idiopathic pulmonary fibrosis. *Expert Opin Drug Saf*. 2016 Jul;15(7):975-982
4. **Shlobin OA, Brown AW, Nathan SD**. Pulmonary Hypertension in Diffuse Parenchymal Lung Diseases.

Chest. 2016 Aug 20. pii: S0012-3692(16)56163-7. doi: 10.1016/j.chest.2016.08.002. [Epub ahead of print] Review.PMID: 27554299

5. **King CS, Nathan SD.** Idiopathic Pulmonary Fibrosis: Impact and Optimal Management of Comorbidities. *Lancet Respir Med.* 2016 Sep 2. pii: S2213-2600(16)30222-3. doi: 10.1016/S2213-2600(16)30222-3. [Epub ahead of print] Review.

EDITORIALS

1. **Nathan SD,** Corris PA. Upfront combination therapy: does the Ambition study herald a new era in the treatment of pulmonary arterial hypertension. *Thorax* 2016;71:107-109 doi:10.1136/thoraxjnl-2015-207854
2. **King CS, Nathan SD.** "Should all patients with IPF, even those with more than moderate impairment, be treated with nintedanib or pirfenidone?" YES. *Chest.* 2016;150(2):273-275
3. Hassoun P, **Nathan SD.** Sildenafil for pulmonary hypertension complicating IPF: a rationale grounded in basic science. *Eur Respir J.* 2016 Jun;47(6):1615-7. doi: 10.1183/13993003.00395-2016.
4. **Nathan SD.** Antiacid therapy and IPF: cause for heartburn? *Lancet Respir Med.* 2016 Mar 31. pii: S2213-2600(16)00102-8. doi: 10.1016/S2213-2600(16)00102-8
5. **King CS, Cochrane A.** The impact of early de novo donor-specific antibodies on lung transplant outcomes: Is timing everything? *J Heart Lung Transplant.* 2016; 35 (9): 1057-8.

BOOK CHAPTERS AND BOOKS

1. **King CS, Nathan SD.** Treatment of Pulmonary Hypertension in Interstitial Lung Disease. For *Pulmonary Hypertension and Interstitial lung disease.* Edited by Robert P. Baughman, Roberto G. Carbone and Steven D. Nathan.
2. **Shlobin OA, Nathan SD.** Rare ILD and PH. For *Pulmonary Hypertension and Interstitial lung disease.* Edited by Robert P. Baughman, Roberto G. Carbone and Steven D. Nathan.
3. **Nathan SD.** Interstitial Lung Disease and Pulmonary Hypertension. Submitted 1/20/15 for *Pulmonary Circulation: Diseases and their treatment, Fourth Edition.* Editors, Peacock, Naeije and Rubin. CRC Press.
4. **Nathan SD, Brown AW, King CS.** Guide to Clinical Management of Idiopathic Pulmonary Fibrosis.

ORIGINAL RESEARCH ABSTRACTS & PRESENTATIONS TO INTERNATIONAL MEETINGS

1. **Weir NA, Shlobin OA, Brown D, Nathan SD, Ahmad S, King C, Brown AW.** Parenchymal Lung Disease in PAH patients managed with Prostanoid Agonists. *J Heart Lung Transplant* 2016;35,4S:A990
2. Siddiqui AH, **Weir NA, Lemma WoldeHanna M, Mazer AJ,** Biancotto A, Cai R, Graninger G, Harper B, Sun J, **Nathan SD,** Danner RL, Solomon MA, Elinoff JM. Serum Cytokine Profiling in Pulmonary Arterial Hypertension. *J Heart Lung Transplant* 2016;35,4S:A1003
3. **Cochrane AB, LoRusso M, Fregoso M, Bowen M, Nathan S, Brown AW.** Hepatitis B Immunity prior to lung transplantation: three shots and you're out? *J Heart Lung Transplant* 2016;35,4S:A187
4. Agbor-Enoh S, Fideli U, Doveikis J, Zhu J, Tunc I, Shah P, Russell S, Feller E, Shah K, Rodrigo M, Shah P, Pham S, Iacono A, **Nathan S,** Orens J, Valentine H. Genomic Research Alliance for Transplantation (GRAFT): A Model for long term transplant studies in Thoracic Organ Transplantation. *J Heart Lung Transplant* 2016;35,4S:A422
5. **Nathan SD,** Baseline characteristics of patients enrolled in a prospective study of Riociguat for pulmonary hypertension associated with Idiopathic Interstitial Pneumonia (RISE-IIP Study). Presented at ATS 2016 May 16th, 2016, San Francisco.
6. **Nathan SD,** Albera C, Costabel U, du Bois RM, Glaspole I, Glassberg MK, King TE, Lancaster L, Lederer DJ, Pereira CA, Swigris JJ, Valeyre D, Noble PW, Day BM, Chou W, Wells AU. Effect of Continued Treatment with Pirfenidone Following a $\geq 10\%$ Relative Decline in Percent Predicted Forced Vital Capacity in Patients with Idiopathic Pulmonary Fibrosis (IPF). Presented at ATS 2016 May 17th, 2016, San Francisco.

7. **Nathan SD**, Yu YF, Terasawa E, MaCaulay D. Spectrum of idiopathic pulmonary fibrosis severity in clinical practice: implications for clinical trial feasibility and design. Presented at ATS 2016 May 17th, 2016, San Francisco.
8. **Magda G, Della-Santina JL, Stayrook SA, Weir N, King C, Ahmad S, Shlobin OA, Brown AW, Della-Santina CP, Nathan SD**. Prevalence of Basilar Fibrosis in a Cohort of Patients with Abdominal CT Imaging. Presented at ATS 2016 May 17th, 2016, San Francisco.
9. **Nathan SD, Stayrook SA, King C, Weir N, Ahmad S, Shlobin OA, Brown AW**. Residual volume-corrected forced vital capacity change: a more accurate indicator of outcomes in IPF? Presented at ATS 2016 May 17th, 2016, San Francisco.
10. Baughman RP, **Nathan SD**, Engel PJ, Scholand MB, Barney J, Culver DA. The use of registry for sarcoidosis associated pulmonary hypertension (ReSAPH) in the design of the riociguat for sarcoidosis associated pulmonary hypertension (RioSAPH) clinical trial. Presented at ATS 2016 May 2016, San Francisco.
11. Glassberg MK, **Nathan SD**, Lin CY, Lew C, Raimundo K, Stauffer J, Chou W, Noble PW. Cardiovascular Events in Phase 3 Trials of Pirfenidone in Idiopathic Pulmonary Fibrosis (IPF). Presented at ATS 2016 May 2016, San Francisco.
12. Glassberg MK, **Nathan SD**, Lew C, Raimundo K, Day BM, Stauffer J, Chou W, Noble PW. Cardiovascular Risk Factors, Comorbidities and Concomitant Medications from Three Phase 3 Trials of Pirfenidone in Idiopathic Pulmonary Fibrosis. Presented at ATS 2016 May 2016, San Francisco.
13. Rodrigues L, Bui S, **Nathan SD**, Grant GM. Could infection be a significant factor in IPF? Presented at ATS 2016 May 2016, San Francisco.
14. Bui S, **Nathan SD**, Chhina MK, **Khandhar S**, Grant GM. Apoptotic challenge evokes differential response mechanisms of Idiopathic Pulmonary Fibrosis fibroblasts. Presented at ATS 2016 May 2016, San Francisco.
15. **Nathan SD**, Albera C, Costabel U, Glaspole I, Glasberg MK, Lancaster L, Lederer DJ, Pereira CA, Swigris JJ, Pavlov A, Stauffer J, Day BM, Chou W, Wells AU. Effect of continued pirfenidone treatment following a \geq 15% decline in 6-minute walk distance (6MWD) in patients with idiopathic pulmonary fibrosis (IPF)—pooled analysis from three pivotal studies. Accepted for podium presentation ERS 2016.
16. **Nathan SD**, Lancaster L, Albera C, Glassberg MK, Swigris J, Gilberg F, Kirchgässler KU, Petzinger U, Noble P. Dose modifications and dose intensity during treatment with pirfenidone. Accepted for podium presentation ERS 2016.
17. Fisher M, Maher T, **Nathan SD**, Hill C, Marshall J, Dejonckheere F, Thuresson PO, Mathew N. Predicting life expectancy for pirfenidone and best supportive care in idiopathic pulmonary fibrosis. Podium presentation at ERS 2016.
18. Noble PW, Albera C, Chou W, Costabel U, Day B, Glaspole I, Glassberg MK, Lancaster L, Lederer DJ, **Nathan SD**, Pereira CA, Stauffer J, Swigris JJ. Annual rate of FVC decline in patients with IPF treated with pirfenidone: pooled analysis from 3 pivotal studies. ERS 2016.
19. Glassberg MK, **Nathan SD**, Day BM, Chou W, Stauffer J, Noble PW. Evaluation of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) With Modifiable Cardiovascular Risk Factors: Pooled Analysis From Three Phase 3 Trials. Submitted to Chest 2016.
20. **King C, Brown AW, Shlobin OA**, Katugaha S, Murphy C, Dalton H. ECMO as a Bridge: Pre- and Post-Lung Transplantation. Annual Extracorporeal Life Support Organization Meeting 2016
21. Weir NA, **Shlobin OA, Brown D, Nathan SD, Ahmad S, King C, Brown AW**. Parenchymal Lung Disease in PAH patients managed with prostacyclin agonists. J Heart Lung Transplant 2016;35, 4S:A990.
22. Barney J, **Shlobin OA**, Culver DA, et al. Sarcoidosis associated Pulmonary Hypertension across the world: results of a Registry of Sarcoidosis Associated Pulmonary Hypertension (RESAPH). Presented at ATS 2016.
23. Magda G, Della-Santina JL, Stayrook SA, Weir N, **King C, Ahmad SA, Shlobin OA, Brown AW, Della-Santina CP, Nathan SD**. Prevalence of basilar fibrosis in a cohort of patients with abdominal CT imaging. Presented at AST 2016.
24. **Nathan SD**, Stayrook SA, **King C, Weir N, Ahmad SA, Shlobin OA, Brown AW**. Residual volume-

corrected FVC change: a more accurate indicator of outcomes in IPF? Presented at ATS 2016.

PRESENTATIONS AT NATIONAL/INTERNATIONAL MEETINGS

1. Pulmonary Hypertension in Sarcoidosis. Tulane Sarcoidosis Conference. New Orleans Feb 27th, 2016. SN
2. Are PH specific medications beneficial in PH-ILD? International Society for Heart and Lung Transplantation, Washington DC. April 27th, 2016. SN
3. New Therapeutic Strategies for IPF. Brazilian Thoracic Society meeting. Rio de Janeiro October 12th, 2016. SN
4. Clinical overview and clinical landscape of lung disease in Rheumatology. Keynote speaker American College of Rheumatology November 11th 2016 Washington DC. SN
5. "Xenotransplantation: Comparison with Human Psychosocial Selection Criteria"
Jane Harrison, LCSW, CCTSW; Society for Transplant Social Work, San Diego, California. 10/8/16
6. VTE Point and Counterpoint: Direct Oral anticoagulants. Chest 2016. Los Angeles, CA. Chris King
7. Venous Thromboembolism: Evolving Strategies – Anticoagulants: A New Age. Chest 2016. Los Angeles, CA. Chris King
8. Clinical Use of Non-vitamin K Oral Anticoagulants. Chest 2016. Los Angeles, CA. Chris King
9. PH Group: Cases and Challenge. 2016 PHA, Dallas, Tx, Oksana Shlobin
10. PH in ILD (session chair). 2016 ISHLT, Washington, DC. Oksana Shlobin